David Borges Sells 906 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 906 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $19.10, for a total value of $17,304.60. Following the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at $112,804.60. This trade represents a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Down 5.5%

Shares of Omeros stock opened at $18.22 on Thursday. The stock has a market cap of $1.32 billion, a P/E ratio of 14.23 and a beta of 2.54. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.65. The business’s 50 day moving average is $12.30 and its 200-day moving average is $11.92.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. On average, sell-side analysts expect that Omeros Corporation will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Omeros in the second quarter valued at approximately $57,484,000. UBS Group AG lifted its holdings in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. California State Teachers Retirement System boosted its stake in Omeros by 19,094.9% in the 2nd quarter. California State Teachers Retirement System now owns 720,192 shares of the biopharmaceutical company’s stock valued at $75,730,000 after purchasing an additional 716,440 shares during the period. Vanguard Group Inc. boosted its stake in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares during the period. Finally, Corient Private Wealth LP acquired a new position in Omeros in the 2nd quarter valued at $6,274,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Finally, Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.